AstraZeneca, Daiichi Sankyo Ink $6 Billion Deal for Lung and Breast Cancer Treatments
By Ruchi Jhonsa, Ph.D. After getting success with Enhertu, a Daiichi Sankyo antibody drug-conjugate (ADC) targeting breast cancer, AstraZeneca has decided to strengthen this collaboration further by entering a $6 …
Read More